REVA Medical to Hold Briefing Call on Financial Results for Q3 2012

| Source: REVA Medical Inc

SAN DIEGO, Nov. 6, 2012 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a conference call to discuss the Company's financial results through September 30, 2012 and its business outlook. Robert Stockman, Chairman and CEO, will host the call.

The call is scheduled for 2:00 p.m. US PST on Tuesday, November 13, 2012 (or 9:00 a.m. AEDT on Wednesday, 14 November 2012) and may be accessed within the United States by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing (02) 8223 9876. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly. A replay of the audiocast will be available on the Company's website at following the call.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. REVA's initial product, the ReZolve® scaffold, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.

The REVA Medical, Inc. logo is available at

United States

Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045


Investor Enquiries:
Kim Jacobs or Alan Taylor
Inteq Limited
+61 2 9231 3322

Media Enquiries:
Haley Price or Rebecca Wilson
Buchan Consulting
+61 3 9866 4722